Opus Genetics Files 8-K for Bylaw Amendments & Financials
Ticker: IRD · Form: 8-K · Filed: Mar 20, 2025 · CIK: 1228627
Sentiment: neutral
Topics: corporate-governance, financial-reporting, amendment
TL;DR
Opus Genetics filed an 8-K for bylaw changes and financials.
AI Summary
On March 19, 2025, Opus Genetics, Inc. filed an 8-K report. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws, other events, and financial statements and exhibits. The company, previously known as Ocuphire Pharma, Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This 8-K filing indicates potential changes in Opus Genetics' corporate governance or structure and provides updates on its financial reporting, which are crucial for investors to assess the company's operational status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative news or events.
Key Players & Entities
- Opus Genetics, Inc. (company) — Registrant
- Ocuphire Pharma, Inc. (company) — Former company name
- REXAHN PHARMACEUTICALS, INC. (company) — Former company name
- CORPORATE ROAD SHOW DOT COM INC (company) — Former company name
- March 19, 2025 (date) — Date of earliest event reported
- 20250319 (date) — Conformed period of report
- 20250320 (date) — Filing date
FAQ
What specific amendments were made to Opus Genetics, Inc.'s Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the provided text excerpt.
What are the 'Other Events' reported by Opus Genetics, Inc. on March 19, 2025?
The filing lists 'Other Events' as an item information category, but the specific nature of these events is not detailed in the provided text.
What is the significance of Opus Genetics, Inc. filing 'Financial Statements and Exhibits'?
This indicates that the company is providing updated financial information and related documents as part of its regulatory reporting requirements.
When did Opus Genetics, Inc. change its name from Ocuphire Pharma, Inc.?
The filing states the date of name change from Ocuphire Pharma, Inc. was November 9, 2020.
What is the Standard Industrial Classification (SIC) code for Opus Genetics, Inc.?
The SIC code for Opus Genetics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 20, 2025 regarding Opus Genetics, Inc. (IRD).